Community Practice Connections™: Modifying the Course of Sickle Cell Disease With Modern Interventions

Released On
February 4, 2022

Expires On
February 4, 2023

Media Type

Completion Time
90 minutes

Hematology, Pediatrics, Emergency Medicine

Bleeding Disorders, Pain

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.


This activity is supported by an educational grant from Global Blood Therapeutics, Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 2.5 Contact Hours

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

The target audience for this activity is hematologists, specialty nurse practitioners, physician assistants, and registered nurses who treat patients with sickle cell disease. Other health care professionals interested in the treatment of sickle cell disease are also invited to participate.

Program Overview

Sickle cell disease consists of a group of rare genetic blood disorders which are responsible for serious life-threatening complications. In the past several years, a greater understanding of the pathogenesis of these subtypes has led to a number of new and emerging agents that have revolutionized the treatment for these malignancies.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a live satellite symposium presented at the 63rd American Society of Hematology (ASH) Annual Meeting held in December 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with sickle cell disease, putting recent trial data into clinical context. The program is designed both for those who did not attend the live meeting and to help reinforce learnings for those who did.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the impact of poorly managed sickle cell disease on patient outcomes
  • Evaluate the role of disease-modifying therapies in the management of patients with sickle cell disease
  • Describe the effects of health inequities on the management of complications of sickle cell disease
  • Select personalized treatment strategies to reduce complications associated with sickle cell disease



Elliott Vichinsky, MD

Professor of Pediatrics
The University of California, San Francisco (UCSF)
Director of Hematology/Oncology
UCSF Benioff Children’s Hospital Oakland
Director, Northern California Sickle Cell and Thalassemia Centers
San Francisco, CA


Caterina P. Minniti, MD

Professor of Clinical Medicine and Pediatrics
Albert Einstein College of Medicine
Bronx, NY


Modupe Idowu, MD

Associate Professor, Hematology
McGovern Medical School
Medical Director, UT Physicians Comprehensive Sickle Cell Center
The University of Texas Health Science Center
Houston, TX

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.5 Contact Hours.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Elliott Vichinsky, MD
  • Grant/Research Support: Agios, Chiesi, Forma Therapeutics, Global Blood Therapeutics
  • Consultant: Chiesi, Forma Therapeutics, Global Blood Therapeutics
Caterina P. Minniti, MD
  • Consultant: Global Blood Therapeutics, Novartis, Forma Therapeutics, Roche, Novo Nordisk, Chiesi, Agios Pharmaceuticals, bluebird bio
Modupe Idowu, MD
  • Grant/Research Support: Novartis, Forma Therapeutics, Global Blood Therapeutics, Pfizer, Cyclerion Therapeutics
  • Speaker’s Bureau: Global Blood Therapeutics

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.